Efficacy and toxicity of CAR T‐cell therapy in patients with primary and secondary central nervous system lymphoma—an analysis of the EBMT Lymphoma WP and the GoCART coalition.

Autor:	Laube, A., Fuhrmann, S., Peczynski, C., Boumendil, A., Michel, E., Finel, H., Galimard, J., Beauvais, D., Daskalakis, M., Novak, U., Kröger, N., Stelljes, M., von Tresckow, B., Wulf, G. G., Dreger, P., Sureda, A., Schmitz, N., Glaß, B.
Předmět:	CENTRAL nervous system DIFFUSE large B-cell lymphomas LYMPHOMAS T cells
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p454-456, 3p
Abstrakt:	B Conclusion: b With a 51% OS-rate at 12 months CART seem to be a very effective therapeutic option in heavily pre-treated r/r PCNSL or SCNSL, particularly for pts being refractory to prior therapy. Pts with involvement of the CNS were excluded from most CART trials; however, anecdotal reports suggest that CART might be an effective treatment option for such pts. B Introduction: b The prognosis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and involvement of the central nervous system (CNS) remains dismal. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text